1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Swiss Exchange  -  05/19 11:30:32 am EDT
85.69 CHF   -1.51%
05/16GLOBAL MARKETS LIVE : Pfizer, Tesla, Holcim, Novartis, Ford...
05/13Avantor Names Jonathan Peacock Chairman
MT
05/13EQT pushes back Galderma IPO plans amid market turmoil - sources
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wolfe Research Lowers Price Target on Novartis, Maintains Outperform Recommendation

12/29/2021 | 07:56am EDT


© MT Newswires 2021
All news about NOVARTIS AG
05/16GLOBAL MARKETS LIVE : Pfizer, Tesla, Holcim, Novartis, Ford...
05/13Avantor Names Jonathan Peacock Chairman
MT
05/13EQT pushes back Galderma IPO plans amid market turmoil - sources
RE
05/12Molecular Partners Swings to Q1 Profit on In-licensing Payment from Novartis
MT
05/12Novartis data at ASCO and EHA showcase latest oncology research and innovation, includi..
GL
05/11New class of cancer drugs down, not out, after Roche trial setback - analysts
RE
05/09Wolfe Research Downgrades Novartis to Peer Perform From Outperform
MT
05/05Novartis Pauses Radioligand Therapy Production Sites in US, Italy Over Quality Issues
MT
05/05Novartis Temporarily Suspends Two Cancer Drugs' Production Amid Quality Concerns -- Sha..
MT
05/05NOVARTIS : provides update on production of radioligand therapy medicines
PU
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2022 52 853 M - -
Net income 2022 9 322 M - -
Net Debt 2022 7 633 M - -
P/E ratio 2022 20,1x
Yield 2022 3,77%
Capitalization 191 B 191 B -
EV / Sales 2022 3,76x
EV / Sales 2023 3,60x
Nbr of Employees 110 000
Free-Float 88,1%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 88,04 $
Average target price 94,70 $
Spread / Average Target 7,56%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG8.37%191 223
JOHNSON & JOHNSON2.59%461 811
PFIZER, INC.-14.65%282 789
ABBVIE INC.12.58%269 361
ELI LILLY AND COMPANY6.87%265 718
ROCHE HOLDING AG-15.26%264 329